Time to first SCA-related hospitalization. Probability of not requiring a SCA-related hospitalization during the blinded treatment period is shown as a Kaplan-Meier graph for patients receiving canakinumab (red line) or placebo (blue line), with the number of patients at risk shown at 4-week intervals. Correspondingly shaded areas represent 95% CI.